乳腺浸润性导管癌组织中CD90、CD32的表达及病理特征
|
摘要
【目的】检测乳腺浸润性导管癌组织中间质干细胞表面标记物(CD90、CD32)的表达,并探讨其与临床、病理特征和预后的关系。【方法】对61例实施手术的乳腺癌患者临床资料进行回顾,术后病理检查均证实为乳腺浸润性导管癌,且手术切除标本均进行石蜡包埋和存档。采用免疫组化法检测癌症组织和癌旁组织CD90、CD32的表达情况,对比不同临床和病理特征患者乳腺癌组织CD90、CD32阳性表达率,分别采用Logistic回归分析法分析影响乳腺癌复发和死亡的危险因素。【结果】乳腺浸润性导管癌组织中CD90均主要位于细胞浆及细胞膜中,以棕色或褐色为阳性染色,呈高表达;CD32主要位于细胞膜中,而胞浆中仅少量表达,以棕色或黄色为阳性染色,呈高表达;癌旁组织CD90和CD44均为阴性表达;乳腺浸润性导管癌组织中CD90、CD32阳性表达率均高于癌旁组织(P<0.05);Ⅲ～Ⅳ期、低分化、淋巴结转移、最大肿瘤直径>5 cm者乳腺浸润性导管癌组织CD90、CD32阳性表达率均分别高于Ⅰ～Ⅱ期、中高分化、无淋巴结转移、最大肿瘤直径≤5 cm者(P<0.05);本组病例中复发率和死亡率分别为32.79%和18.03%。Logistic回归分析显示,临床分期Ⅲ～Ⅳ期、低分化、有淋巴结转移、肿瘤最大直径>5 cm、CD90阳性表达、CD32阳性表达均是影响乳腺浸润性导管癌复发的危险因素(OR=4.586、5.133、5.972、5.102、6.175、4.322,P<0.05),且均是影响乳腺浸润性导管癌死亡的危险因素(OR=4.217、4.996、5.403、4.815、5.002、4.149,P<0.05)。【结论】乳腺浸润性导管癌组织中CD90和CD32均呈高表达,且与临床、病理特征均紧密相关,均是远期复发和死亡的独立危险因素。
【Objective】To detect the expression of surface markers(CD90 and CD32) of mesenchymal stem cells in invasive ductal carcinoma of breast, and explore their relationships with clinic, pathology features and prognosis.【Methods】The clinical data of 61 patients with breast cancer who underwent the operation were reviewed. Postoperative pathological examination showed that all were invasive ductal carcinoma of breast. Paraffin embedding and archiving were performed in all resected specimens. Streptavidin-perosidase method was used to detect the expression of CD90 and CD32 in cancer tissues and adjacent tissues. The positive expression rates of CD90 and CD32 in breast cancer tissues with different clinical and pathological features were compared. Logistic regression analysis was used to analyze the risk factors of recurrence and death of breast cancer respectively.【Results】CD90 was mainly located in the cytoplasm and cell membrane of invasive ductal carcinoma of breast, with brown as positive staining, showing high expression. CD32 was mainly located in cell membrane, with only a small amount of expression in cytoplasm, brown or yellow as positive staining, showing high expression. The expression of CD90 and CD44 was negative in paracancerous tissues. The positive expression rates of CD90 and CD32 in breast cancer tissues were higher than those in adjacent tissues(P<0.05). The positive expression rates of CD90 and CD32 in breast cancer tissues of Ⅲ～Ⅳ stage, low differentiation, lymph node metastasis and maximum tumor diameter> 5 cm were higher than those of Ⅰ～Ⅱ stage, middle high differentiation, no lymph node metastasis and maximum tumor diameter ≤ 5 cm(P<0.05). The recurrence rate and mortality rate were 32.79% and 18.03% respectively. Logistic regression analysis showed that clinical stage Ⅲ～Ⅳ, low differentiation,lymph node metastasis, tumor diameter > 5 cm, positive expression of CD90 and positive expression of CD32 were the risk factors for breast cancer recurrence(OR = 4.586, 5.133, 5.972, 5.102, 6.175, 4.322, P<0.05), which were also the risk factors for breast cancer death(OR=4.217, 4.996, 5.403, 4.815, 5.002, 4.149, P<0.05).【Conclusion】Both CD90 and CD32 are highly expressed in the tissues of invasive ductal carcinoma of breast, which are closely related to clinical and pathological features. They are independent risk factors for long-term recurrence and death.
【Objective】To detect the expression of surface markers(CD90 and CD32) of mesenchymal stem cells in invasive ductal carcinoma of breast, and explore their relationships with clinic, pathology features and prognosis.【Methods】The clinical data of 61 patients with breast cancer who underwent the operation were reviewed. Postoperative pathological examination showed that all were invasive ductal carcinoma of breast. Paraffin embedding and archiving were performed in all resected specimens. Streptavidin-perosidase method was used to detect the expression of CD90 and CD32 in cancer tissues and adjacent tissues. The positive expression rates of CD90 and CD32 in breast cancer tissues with different clinical and pathological features were compared. Logistic regression analysis was used to analyze the risk factors of recurrence and death of breast cancer respectively.【Results】CD90 was mainly located in the cytoplasm and cell membrane of invasive ductal carcinoma of breast, with brown as positive staining, showing high expression. CD32 was mainly located in cell membrane, with only a small amount of expression in cytoplasm, brown or yellow as positive staining, showing high expression. The expression of CD90 and CD44 was negative in paracancerous tissues. The positive expression rates of CD90 and CD32 in breast cancer tissues were higher than those in adjacent tissues(P<0.05). The positive expression rates of CD90 and CD32 in breast cancer tissues of Ⅲ～Ⅳ stage, low differentiation, lymph node metastasis and maximum tumor diameter> 5 cm were higher than those of Ⅰ～Ⅱ stage, middle high differentiation, no lymph node metastasis and maximum tumor diameter ≤ 5 cm(P<0.05). The recurrence rate and mortality rate were 32.79% and 18.03% respectively. Logistic regression analysis showed that clinical stage Ⅲ～Ⅳ, low differentiation,lymph node metastasis, tumor diameter > 5 cm, positive expression of CD90 and positive expression of CD32 were the risk factors for breast cancer recurrence(OR = 4.586, 5.133, 5.972, 5.102, 6.175, 4.322, P<0.05), which were also the risk factors for breast cancer death(OR=4.217, 4.996, 5.403, 4.815, 5.002, 4.149, P<0.05).【Conclusion】Both CD90 and CD32 are highly expressed in the tissues of invasive ductal carcinoma of breast, which are closely related to clinical and pathological features. They are independent risk factors for long-term recurrence and death.
引文
[1]王乐,张玥,石菊芳,等.中国女性乳腺癌疾病负担分析[J].中华流行病学杂志, 2016, 37(7):970-976.
[2]徐兵河,江泽飞,胡夕春.中国晚期乳腺癌临床诊疗专家共识2016[J].中华医学杂志, 2016, 96(22):1719-1727.
[3]王安安,吴恒宇,刘磊,等.三阴性乳腺癌组织中肿瘤干细胞相关标记物CD44+/CD24-/low和ALDH1+的表达及意义[J].中国医学创新, 2017, 14(25):23-27.
[4]周四莲,匡志鹏. CD90和CD44分子在人肝癌组织中的表达[J].中国癌症防治杂志, 2017, 9(3):185-189.
[5] Zhang K, Chen X, Zhou J, et al. Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility:a meta-analysis based on 3906 subjects[J]. Oncotarget, 2017, 8(27):45020-45029.
[6]黄香,殷咏梅. 2018年中国临床肿瘤学会乳腺癌治疗指南更新要点[J].中华医学杂志, 2018, 97(16):162-164.
[7]殷茜,胡艺冰,罗智勇,等. Twist沉默介导的间充质-上皮转化对乳腺癌干细胞特性的影响[J].中华实验外科杂志,2016, 33(10):2341-2343.
[8] Hillebrand LE, Bengsch F, Hochrein J, et al. Proteolysis-a characteristic of tumor-initiating cells in murine metastatic breast cancer[J]. Oncotarget, 2016, 7(36):58244-58260.
[9] Wajid N, Azam M, Khalid S, et al. Improvement in Therapeutic Ability of Wharton's Jelly Derived Mesenchymal Stem Cells with Vitamin E in Breast Cancer[J]. J Coll Physicians Surg Pak, 2017, 27(12):754-758.
[10]李和军,刘宁,李频,等. CD32在人肝癌细胞株上的表达[J].中国老年学, 2010, 30(4):498-499.
[11]韩涛,童雅兰,刘军灵,等.泛素样蛋白D调控乳腺癌干细胞对乳腺癌生物学行为的影响[J].临床误诊误治, 2016,29(4):105-109.
[12]杨海玉,刘勇,戴艳枝,等.乳腺浸润性导管癌不同分子分型中CD90的表达及其意义[J].临床与实验病理学杂志, 2017, 33(3):245-249.
[13]杨园园,樊伯珍,童晓文.人类间充质干细胞与卵巢癌细胞间的相互作用研究[J].中华医学杂志, 2015, 95(23):1849-1853.
[14]Kim HA, Choi B, Suh CH, et al. Highly Expression of CD11b and CD32 on Peripheral Blood Mononuclear Cells from Patients with Adult-Onset Still's Disease[J]. Int J Mol Sci,2017, 18(1):1082-1093.
[15]刘乔飞,廖泉,宗毅,等.免疫健全小鼠Panc02胰腺癌发展过程中髓系来源抑制细胞与肿瘤相关巨噬细胞动态变化[J].中华实验外科杂志, 2014, 31(11):2430-2433.
[2]徐兵河,江泽飞,胡夕春.中国晚期乳腺癌临床诊疗专家共识2016[J].中华医学杂志, 2016, 96(22):1719-1727.
[3]王安安,吴恒宇,刘磊,等.三阴性乳腺癌组织中肿瘤干细胞相关标记物CD44+/CD24-/low和ALDH1+的表达及意义[J].中国医学创新, 2017, 14(25):23-27.
[4]周四莲,匡志鹏. CD90和CD44分子在人肝癌组织中的表达[J].中国癌症防治杂志, 2017, 9(3):185-189.
[5] Zhang K, Chen X, Zhou J, et al. Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility:a meta-analysis based on 3906 subjects[J]. Oncotarget, 2017, 8(27):45020-45029.
[6]黄香,殷咏梅. 2018年中国临床肿瘤学会乳腺癌治疗指南更新要点[J].中华医学杂志, 2018, 97(16):162-164.
[7]殷茜,胡艺冰,罗智勇,等. Twist沉默介导的间充质-上皮转化对乳腺癌干细胞特性的影响[J].中华实验外科杂志,2016, 33(10):2341-2343.
[8] Hillebrand LE, Bengsch F, Hochrein J, et al. Proteolysis-a characteristic of tumor-initiating cells in murine metastatic breast cancer[J]. Oncotarget, 2016, 7(36):58244-58260.
[9] Wajid N, Azam M, Khalid S, et al. Improvement in Therapeutic Ability of Wharton's Jelly Derived Mesenchymal Stem Cells with Vitamin E in Breast Cancer[J]. J Coll Physicians Surg Pak, 2017, 27(12):754-758.
[10]李和军,刘宁,李频,等. CD32在人肝癌细胞株上的表达[J].中国老年学, 2010, 30(4):498-499.
[11]韩涛,童雅兰,刘军灵,等.泛素样蛋白D调控乳腺癌干细胞对乳腺癌生物学行为的影响[J].临床误诊误治, 2016,29(4):105-109.
[12]杨海玉,刘勇,戴艳枝,等.乳腺浸润性导管癌不同分子分型中CD90的表达及其意义[J].临床与实验病理学杂志, 2017, 33(3):245-249.
[13]杨园园,樊伯珍,童晓文.人类间充质干细胞与卵巢癌细胞间的相互作用研究[J].中华医学杂志, 2015, 95(23):1849-1853.
[14]Kim HA, Choi B, Suh CH, et al. Highly Expression of CD11b and CD32 on Peripheral Blood Mononuclear Cells from Patients with Adult-Onset Still's Disease[J]. Int J Mol Sci,2017, 18(1):1082-1093.
[15]刘乔飞,廖泉,宗毅,等.免疫健全小鼠Panc02胰腺癌发展过程中髓系来源抑制细胞与肿瘤相关巨噬细胞动态变化[J].中华实验外科杂志, 2014, 31(11):2430-2433.